The Synthesis of Nano-Doxorubicin and its Anticancer Effect

(E-pub Ahead of Print)

Author(s): Lusha Zhu, Mei Lin*

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Become EABM
Become Reviewer
Call for Editor


Doxorubicin (DOX) is widely used as a clinical first-line anti-cancer drug. However, its clinical application is severely limited due to the lack of tumor specificity of the drug and severe side effects such as myelosuppression, nephrotoxicity, dose-dependent cardiotoxicity, and multi-drug resistance. To improve the bioavailability of DOX, maximize the therapeutic effect, and reduce its toxic and side effects, many studies have been done on the nanoformulations of DOX, such as liposomes, polymer micelles, dendrimer, nanogels. Herein, we review the latest progress of DOX nano-preparations and their anti-tumor effects, hoping to provide theoretical references and new research ideas for the development of new dosage forms of the drug and the technical methods available for clinical application.

Keywords: Doxorubicin, nanotechnology, nanoparticles, synthesis, nanocarrier, drug delivery systems.

Rights & PermissionsPrintExport Cite as

Article Details

Published on: 28 December, 2020
(E-pub Ahead of Print)
DOI: 10.2174/1871520621666201229115612
Price: $95

Article Metrics

PDF: 284